OncoMed Pharmaceuticals, Inc.
Quick facts
Phase 1 pipeline
- OMP-131R10
- OMP-18R5
- OMP-21M18
- OMP-52M51
- OMP-54F28
- OMP-54F28, Nab-Paclitaxel and Gemcitabine
- OMP-54F28, Paclitaxel and Carboplatin
- OMP-54F28 with Sorafenib
- Vantictumab combined with paclitaxel
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: